Verbatim response from Claude
This is a fast-moving area, so I want to be straightforward with you:
What Happened
The FDA declared the semaglutide shortage over (early 2025), which means compounding pharmacies lost legal authority to compound copies of Ozempic/Wegovy. Tirzepatide (Mounjaro/Zepbound) followed similarly.
Current Reality
Many telehealth services had to stop offering compounded GLP-1s or significantly scale back. The landscape is shifting rapidly, and some are still navigating legal challenges.
Services Still in This Space (as of early 2025)
- Hims & Hers - faced FDA pressure but has been fighting it legally
- BodyLogicMD - exploring compliant options
- Mochi Health - shifted toward brand-name access
- Ro - pivoting to brand-name GLP-1s
My Honest Recommendation
Rather than chasing compounded versions (which carry legal and quality uncertainty right now), consider:
- Sesame Care or Ro for brand-name prescriptions with manufacturer savings programs
- Lilly's LillyDirect for Zepbound directly
- Novo Nordisk's NovoCare for Wegovy savings
Important Caveat
This information changes weekly. Check current status directly with each provider, and consult your doctor about safety and legality.
Would you like help finding affordable access to the FDA-approved versions?